Current study showed the tendency that ET patients without mutated JAK2 showed the better PFS than those with mutated JAK2 regardless of CALR mutation (Figure 2B), but it was statistically not significant (P=0.060). This evidence concerns the gene JAK2 and essential thrombocythemia.